Amundi MSCI EMU Value Factor Index Fund logo

Amundi MSCI EMU Value Factor Index Fund (VAL)

Market Closed
30 May, 15:30
£
0. 55
0
0%
£
1.92M Market Cap
- P/E Ratio
0% Div Yield
496,599 Volume
- Eps
£ 0.55
Previous Close
Day Range
0.5 0.6
Year Range
0.38 3.5
Want to track VAL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

VAL closed Friday higher at £0.55, an increase of 0% from Thursday's close, completing a monthly increase of 10% or £0.05. Over the past 12 months, VAL stock lost -29.03%.
VAL is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on XETRA (EUR).

VAL Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Amundi MSCI EMU Value Factor Index Fund (VAL) FAQ

What is the stock price today?

The current price is £0.55.

On which exchange is it traded?

Amundi MSCI EMU Value Factor Index Fund is listed on XETRA.

What is its stock symbol?

The ticker symbol is VAL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 1.92M.

Has Amundi MSCI EMU Value Factor Index Fund ever had a stock split?

No, there has never been a stock split.

Amundi MSCI EMU Value Factor Index Fund Profile

Biotechnology Industry
Healthcare Sector
Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. CEO
LSE Exchange
LU1598690169 ISIN
United Kingdom Country
16 Employees
- Last Dividend
- Last Split
- IPO Date
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.

Contact Information

Address: Stonebridge House
Phone: 44 24 7679 6496